Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Maxcyte (MXCT) over the last 5 years, with Q3 2025 value amounting to 0.27%.

  • Maxcyte's Return on Capital Employed fell 700.0% to 0.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.27%, marking a year-over-year decrease of 700.0%. This contributed to the annual value of 0.22% for FY2024, which is 300.0% down from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Return on Capital Employed is 0.27%, which was down 700.0% from 0.25% recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Return on Capital Employed registered a high of 0.06% during Q1 2022, and its lowest value of 0.27% during Q3 2025.
  • Its 5-year average for Return on Capital Employed is 0.16%, with a median of 0.19% in 2023.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first changed by 0bps in 2022, then tumbled by -900bps in 2023.
  • Maxcyte's Return on Capital Employed (Quarter) stood at 0.07% in 2021, then tumbled by -47bps to 0.1% in 2022, then crashed by -92bps to 0.19% in 2023, then dropped by -16bps to 0.22% in 2024, then dropped by -19bps to 0.27% in 2025.
  • Its Return on Capital Employed stands at 0.27% for Q3 2025, versus 0.25% for Q2 2025 and 0.23% for Q1 2025.